骨髓增生异常综合征去甲基化治疗:地西他滨还是阿扎胞苷?

[1]	Duong VH,Komrokji RS,List AF.Update on the pharmacotherapy for myelodysplastic syndromes[J].Expert Opin Pharmacother,2014,15:1811-1825.
[2]	中华医学会血液学分会.骨髓增生异常综合征中国诊断与治疗指南(2019年版)[J].中华血液学杂志,2019,40(2):89-97.
[3]	Madanat Y,Sekeres MA.Optimizing the use of hypomethylating agents in myelodysplastic syndromes:Selecting the candidate,predicting the response,and enhancing the activity[J].Semin Hematol,2017,54:147-153.
[4]	Ades L,Itzykson R,Fenaux P.Myelodysplastic syndromes[J].Lancet,2014,383:2239-2252.
[5]	Tobiasson M,Abdulkadir H,Lennartsson A,et al.Comprehensive mapping of the effects of azacitidine on DNA methylation,repressive/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related disease[J].Oncotarget,2017,8:28812-28825.
[6]	Kornblith AB,Herndon JN,Silverman LR,et al.Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial:a Cancer and Leukemia Group B study[J].J Clin Oncol,2002,20:2441-2452.
[7]	Seymour JF,Fenaux P,Silverman LR,et al.Effects of azacitidine compared with conventional care regimens in elderly (>/=75 years) patients with higher-risk myelodysplastic syndromes[J].Crit Rev Oncol Hematol,2010,76:218-227.
[8]	Kantarjian H,Issa JP,Rosenfeld CS,et al.Decitabine improves patient outcomes in myelodysplastic syndromes:results of a phase III randomized study[J].Cancer,2006,106:1794-1803.
[9]	Kantarjian H,Oki Y,Garcia-Manero G,et al.Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia[J].Blood,2007,109:52-57.
[10]	Fenaux P,Mufti GJ,Hellstrom-Lindberg E,et al.Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes:a randomised,open-label,phase III study[J].Lancet Oncol,2009,10:223-232.
[11]	Du X,Lai YY,Xiao Z,et al.Efficacy,safety and pharmacokinetics of subcutaneous azacitidine in Chinese patients with higher risk myelodysplastic syndromes:Results from a multicenter,single-arm,open-label phase 2 study[J].Asia Pac J Clin Oncol,2018,14:270-278.
[12]	Lubbert M,Suciu S,Baila L,et al.Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy:final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group[J].J Clin Oncol,2011,29:1987-1996.
[13]	Lee YG,Kim I,Yoon SS,et al.Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes[J].Br J Haematol,2013,161:339-347.
[14]	Salim O,Toptas T,Avsar E,et al.Azacitidine versus decitabine in patients with refractory anemia with excess blast-Results of multicenter study[J].Leuk Res,2016,45:82-89.
[15]	Zeidan AM,Davidoff AJ,Long JB,et al.Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes[J].Br J Haematol,2016,175:829-840.
[16]	Xie M,Jiang Q,Xie Y.Comparison between decitabine and azacitidine for the treatment of myelodysplastic syndrome:a meta-analysis with 1,392 participants[J].Clin Lymphoma Myeloma Leuk,2015,15:22-28.
[17]	Almasri J,Alkhateeb HB,Firwana B,et al.A systematic review and network meta-analysis comparing azacitidine and decitabine for the treatment of myelodysplastic syndrome[J].Syst Rev,2018,7:144.
[18]	Falantes J,Delgado RG,Calderon-Cabrera C,et al.Multivariable time-dependent analysis of the impact of azacitidine in patients with lower-risk myelodysplastic syndrome and unfavorable specific lower-risk score[J].Leuk Res,2015,39:52-57.
[19]	Garcia-Manero G,Jabbour E,Borthakur G,et al.Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes[J].J Clin Oncol,2013,31:2548-2553.
[20]	叶丽,任艳玲,谢丽丽,等.小剂量地西他滨治疗较低危骨髓增生异常综合征患者疗效初步观察[J].中华血液学杂志,2017,38(4):307-312.
[21]	Jabbour E,Short NJ,Montalban-Bravo G,et al.Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN[J].Blood,2017,130:1514-1522.
[22]	Damaj G,Duhamel A,Robin M,et al.Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes:a study by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-Francophone des Myelodysplasies[J].J Clin Oncol,2012,30:4533-4540.
[23]	Gerds AT,Gooley TA,Estey EH,et al.Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS[J].Biol Blood Marrow Transplant,2012,18:1211-1218.
[24]	Lubbert M,Bertz H,Ruter B,et al.Non-intensive treatment with low-dose 5-aza-2'-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients[J].Bone Marrow Transplant,2009,44:585-588.
[25]	郑慧菲,王婧,周进,等.地西他滨桥接异基因造血干细胞移植治疗骨髓增生异常综合征的疗效分析[J].中华血液学杂志,2015,36(2):121-124.
[26]	Yahng SA,Kim M,Kim TM,et al.Better transplant outcome with pre-transplant marrow response after hypomethylating treatment in higher-risk MDS with excess blasts[J].Oncotarget,2017,8:12342-12354.
[27]	Song LX,Xu L,Li X,et al.Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia[J].Ann Hematol,2012,91:1879-1886.
[28]	Gao S,Li Z,Fu JH,et al.Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes,Which Combined with Complex Karyotype Respectively[J].Asian Pac J Cancer Prev,2015,16:6627-6632.
[29]	王萌,韩好好,郭荣,等.低剂量地西他滨序贯CAG方案治疗MDS-难治性贫血伴有原始细胞过多的临床疗效[J].中国实验血液学杂志,2017,25(5):1482-1486.
[30]	Ye XN,Zhou XP,Wei JY,et al.Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms[J].Leuk Lymphoma,2016,57:1311-1318.
[31]	Shahrabi S,Khosravi A,Shahjahani M,et al.Genetics and Epigenetics of Myelodysplastic Syndromes and Response to Drug Therapy:New Insights[J].Oncol Rev,2016,10:311.
[32]	Sekeres MA,Othus M,List AF,et al.Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia:North American Intergroup Study SWOG S1117[J].J Clin Oncol,2017,35:2745-2753.
[33]	Garcia-Manero G,Montalban-Bravo G,Berdeja JG,et al.Phase 2,randomized,double-blind study of pracinostat in combination with azacitidine in patients with untreated,higher-risk myelodysplastic syndromes[J].Cancer,2017,123:994-1002.
[34]	Issa JP,Garcia-Manero G,Huang X,et al.Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia[J].Cancer,2015,121:556-561.
[35]	Prebet T,Sun Z,Figueroa ME,et al.Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes:results of the US Leukemia Intergroup trial E1905[J].J Clin Oncol,2014,32:1242-1248.
[36]	Mcgraw KL,Basiorka AA,Johnson JO,et al.Lenalidomide induces lipid raft assembly to enhance erythropoietin receptor signaling in myelodysplastic syndrome progenitors[J].PLoS One,2014,9:e114249.
[37]	Sekeres MA,Tiu RV,Komrokji R,et al.Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes[J].Blood,2012,120:4945-4951.
[38]	L A,A G,K L,et al.A Randomized Phase II Study of Azacitidine (AZA) Alone or with Lenalidomide (LEN),Valproic Acid (VPA) or Idarubicin (IDA) in Higher-Risk MDS:Gfm's 'pick a Winner' Trial[J].Blood,2018,132:467.
[39]	Yang H,Bueso-Ramos C,Dinardo C,et al.Expression of PD-L1,PD-L2,PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents[J].Leukemia,2014,28:1280-1288.
[40]	G G,Ng D,G M,et al.A Phase II Study Evaluating the Combination of Nivolumab (Nivo) or Ipilimumab (Ipi) with Azacitidine in Pts with Previously Treated or Untreated Myelodysplastic Syndromes (MDS)[J].Blood,2016,128:344.
[41]	Jilg S,Reidel V,Muller-Thomas C,et al.Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients[J].Leukemia,2016,30:112-123.
[42]	Dinardo CD,Pratz K,Pullarkat V,et al.Venetoclax combined with decitabine or azacitidine in treatment-naive,elderly patients with acute myeloid leukemia[J].Blood,2019,133:7-17.
[43]	Dinardo CD,Rausch CR,Benton C,et al.Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies[J].Am J Hematol,2018,93:401-407.
[44]	Stone RM,Mandrekar SJ,Sanford BL,et al.Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation[J].N Engl J Med,2017,377:454-464.
[45]	Strati P,Kantarjian H,Ravandi F,et al.Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome[J].Am J Hematol,2015,90:276-281.
[46]	Athuluri-Divakar SK,Vasquez-Del CR,Dutta K,et al.A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling[J].Cell,2016,165:643-655.
[47]	Garcia-Manero G,Fenaux P,Al-Kali A,et al.Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME):a randomised,controlled,phase 3 trial[J].Lancet Oncol,2016,17:496-508.
[48]	Navada SC,Guillermo Garcia-Manero,Atallah EL,et al.Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS):Efficacy and Safety Results in HMA Treatment Naive & Relapsed (Rel)/Refractory (Ref) Patients[J].Blood,2018,132:230.